Chris Chen, CEO of WuXi Biologics, discusses his organization’s approach to ensuring consistent quality, reliability, and speed of biologics development and manufacturing.
Ipsen invested in containment and transfer equipment at Quotient’s Pennsylvania facility to support ongoing commercial production of a highly potent therapy for an ultra-rare disease.
The collaboration is designed to align GMP RNA production with cell processing to reduce technical handoffs, accelerate clinical timelines, and strengthen U.S. supply chain.
Tariff refunds are a leadership call for pharmaceutical manufacturers, and executives are weighing whether recovery efforts justify the operational lift.
